Grace Therapeutics, Inc. (GRCE) Operating cash flow 2020–2026
Grace Therapeutics, Inc. (GRCE) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$8.9MFY2026 · since FY2020: -$23.0M → -$8.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$8.9M | +40.5% |
| FY2025 | -$14.9M | -20.8% |
| FY2024 | -$12.3M | +22.5% |
| FY2023 | -$15.9M | +7.7% |
| FY2022 | -$17.2M | -20.4% |
| FY2021 | -$14.3M | +37.6% |
| FY2020 | -$23.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GRCE financial trends
GRCE RevenueGRCE Net incomeGRCE Net marginGRCE Gross profitGRCE Gross marginGRCE Operating incomeGRCE Operating marginGRCE Free cash flowGRCE Capital expendituresGRCE Return on equityGRCE Stock buybacksGRCE Dividends paidGRCE Total assetsGRCE Total liabilitiesGRCE Shareholders’ equityGRCE overview →